Icecure Medical (ICCM) has released an update.
IceCure Medical recently announced impressive results for its ProSense® Cryoablation System at the Japanese Breast Cancer Society Annual Meeting, with studies showing a 99.74% recurrence-free rate for breast cancer patients, and in some cases, zero recurrence over five years. The minimally invasive system, which destroys tumors by freezing, is gaining traction in Japan as IceCure’s partner plans to seek regulatory approval in early 2025. These positive outcomes position ProSense® as a potential alternative to surgical tumor removal, offering significant benefits in terms of efficacy, recovery, and cosmetic results.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.
